These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 18347009)
1. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders. Hultqvist M; Nandakumar KS; Björklund U; Holmdahl R Ann Rheum Dis; 2009 Jan; 68(1):130-5. PubMed ID: 18347009 [TBL] [Abstract][Full Text] [Related]
2. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Hultqvist M; Nandakumar KS; Björklund U; Holmdahl R Ann Rheum Dis; 2010 Aug; 69(8):1527-32. PubMed ID: 20542961 [TBL] [Abstract][Full Text] [Related]
3. The novel anti-rheumatic compound Rabeximod impairs differentiation and function of human pro-inflammatory dendritic cells and macrophages. Giusti P; Frascaroli G; Tammik C; Gredmark-Russ S; Söderberg-Nauclér C; Varani S Immunobiology; 2011; 216(1-2):243-50. PubMed ID: 20494473 [TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory treatment of traumatic brain injury with Rabeximod reduces cerebral antigen presentation in mice. Israelsson C; Kylberg A; Björklund U; Ebendal T J Neurosci Res; 2015 Oct; 93(10):1519-25. PubMed ID: 26068706 [TBL] [Abstract][Full Text] [Related]
5. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Lange F; Bajtner E; Rintisch C; Nandakumar KS; Sack U; Holmdahl R Ann Rheum Dis; 2005 Apr; 64(4):599-605. PubMed ID: 15345503 [TBL] [Abstract][Full Text] [Related]
6. Mouse models of autoimmune diseases. Marques A; Müller S Curr Drug Discov Technol; 2009 Dec; 6(4):262-9. PubMed ID: 20025594 [TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive activity of 15-deoxyspergualin (15-DOS) on various models of rheumatoid arthritis. Schorlemmer HU; Bartlett RR; Schleyerbach R; Seiler FR Drugs Exp Clin Res; 1991; 17(10-11):471-84. PubMed ID: 1841036 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of human amniotic membrane-derived cells on experimental arthritis and other inflammatory disorders. Parolini O; Souza-Moreira L; O'Valle F; Magatti M; Hernandez-Cortes P; Gonzalez-Rey E; Delgado M Arthritis Rheumatol; 2014 Feb; 66(2):327-39. PubMed ID: 24504805 [TBL] [Abstract][Full Text] [Related]
9. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease. Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538 [TBL] [Abstract][Full Text] [Related]
10. Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models. Leung PS; Shu SA; Kenny TP; Wu PY; Tao MH Autoimmun Rev; 2010 Mar; 9(5):A400-5. PubMed ID: 20035901 [TBL] [Abstract][Full Text] [Related]
11. Coenzyme Q10 suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice. Jhun J; Lee SH; Byun JK; Jeong JH; Kim EK; Lee J; Jung YO; Shin D; Park SH; Cho ML Immunol Lett; 2015 Aug; 166(2):92-102. PubMed ID: 26045320 [TBL] [Abstract][Full Text] [Related]
12. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Bartlett RR; Brendel S; Zielinski T; Schorlemmer HU Transplant Proc; 1996 Dec; 28(6):3074-8. PubMed ID: 8962190 [No Abstract] [Full Text] [Related]
13. Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. Gelderman KA; Hultqvist M; Olsson LM; Bauer K; Pizzolla A; Olofsson P; Holmdahl R Antioxid Redox Signal; 2007 Oct; 9(10):1541-67. PubMed ID: 17678439 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Feldmann M; Maini RN Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034 [TBL] [Abstract][Full Text] [Related]
15. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Burkhardt H; Kalden JR Rheumatol Int; 1997; 17(3):85-90. PubMed ID: 9352601 [TBL] [Abstract][Full Text] [Related]
17. Mouse Models of Rheumatoid Arthritis. Caplazi P; Baca M; Barck K; Carano RA; DeVoss J; Lee WP; Bolon B; Diehl L Vet Pathol; 2015 Sep; 52(5):819-26. PubMed ID: 26063174 [TBL] [Abstract][Full Text] [Related]
18. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Murakami Y; Akahoshi T; Aoki N; Toyomoto M; Miyasaka N; Kohsaka H Arthritis Rheum; 2009 Jun; 60(6):1615-23. PubMed ID: 19479878 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis. Xu H; Wang J; Wang C; Chang G; Lin Y; Zhang H; Zhang H; Li Q; Pang T Mol Med Rep; 2015 Jan; 11(1):489-93. PubMed ID: 25351212 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of therapeutic efficacy of Majoon Suranjan, a Unani formulation, in the treatment of rheumatoid arthritis: an experimental study. Subramaneyaan M; Yasmeen S; Ahmed RS; Arora VK; Tripathi AK; Banerjee BD Exp Biol Med (Maywood); 2013 Dec; 238(12):1379-87. PubMed ID: 24006307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]